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Case presentation
A 57-year-old white man was admitted to the hospital for the last time
one year ago. He had been hospitalized 24 years ago because of
increasing abdominal girth, and a diagnosis of ascites due to crypto-
genic cirrhosis was made at that time. The patient was not alcoholic,
had not been exposed to hepatotoxins, and had never suffered from
viral hepatitis. He had been previously hospitalized for insomnia and
depression and for a cholecystectomy 29 years ago.
Six years ago, the patient was diagnosed as having non-insulin-
dependent diabetes mellitus and had been treated with diet and oral
agents. Between 6 and 24 years ago, the ascites was either minimal or
absent and, when present, had been easily controlled by dietary salt
restriction. Six years ago, spironolactone was prescribed to control the
increasing ascites. Initially, this therapy was successful, but over the
past 2 years, the patient had come to the outpatient clinic on an
intermittent basis to receive paracentesis and intravenous salt-poor
albumin replacement.
Two months prior to his final admission, the patient had been in good
health with a normal serum creatinine and electrolytes. He began to
complain of a painful left foot in the absence of trauma. Over the next
month the big toe of the left foot gradually turned black and the
discoloration extended to other toes. On the morning of admission, he
had been found unconscious in bed and was brought to the Emergency
Room by ambulance. On examination he was emaciated and had gross
ascites; the spleen was markedly enlarged, but the liver was not
palpable. Several toes of the left foot were gangrenous, and the vascular
supply to both legs was markedly reduced. His medications at that time
included spironolactone, furosemide, misoprostol, glyburide, and meth-
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otrimeprazine. Markedly hypoglycemic, he responded to intravenous
glucose. Serum electrolytes at the time of admission were normal; the
serum creatinine was 1.1 mg/dl.
Four liters of ascites were removed by paracentesis, and he was
scheduled for bypass surgery to both femoropopliteal arterial systems.
Although the surgery was uneventful, his condition deteriorated quickly
in the postoperative period. He became progressively more febrile and
neutropenic and all surgical incisions became badly infected, growing
multiple organisms. Multiple antibiotics were required over the next 2
months, including vancomycin, neomycin, ciprofloxacin, and various
aminoglycosides and cephalosporins. The left foot became progres-
sively gangrenous and a below-the-knee amputation was performed.
Further extensive plastic surgery was required at the left operative site
to repair an infected graft. Approximately one month after the ampu-
tation, the patient developed extensive vomiting and upper gastrointes-
tinal bleeding. Urine volume fell progressively to oliguric ranges and the
serum creatinine rose to 3.8 mg/dl. Serum sodium was 127 mEq/liter
and serum bicarbonate fell from 24 to 15 mEq/liter; blood urea nitrogen
rose to 70 mg/dl. The abdomen was grossly distended with ascites, and
the arterial blood pressure, which had been 130/80 mm Hg, declined to
110/60mm Hg. The pulse was rapid at 96 beats/mm. Despite attempts at
gradual volume expansion, the patient became progressively more
oliguric (150 mI/day), the serum creatinine rose further to 6.0 mg/dl, and
the serum sodium declined to 119 mEq/liter. The patient died 3 months
after admission with a diagnosis of hepatorenal syndrome.
Discussion
DR. MORTIMER LEVY (Senior Physician, Royal Victoria
Hospital; Director of Nephrology Division; and Professor of
Physiology and Medicine, McGill University, Montreal, Cana-
da): Since its inception in July 1978 [1], the Nephrology Forum
has devoted three issues to the renal and electrolyte problems
of patients with advanced cirrhosis of the liver. Each of the
cases discussed in these presentations highlights the main
problems facing the physician caring for the cirrhotic patient:
how to manage progressive oliguria and azotemia, and whether
these perturbations represent prerenal failure, acute tubular
necrosis (ATN), or hepatorenal syndrome (HRS). I would like
to take a moment to briefly review the two patients previously
presented.
The patient discussed by Dr. Norman Levinsky in the inau-
gural installment of Nephrology Forum was a 36-year-old man
who had had numerous hospital admissions for complications of
advanced alcoholic cirrhosis 111. During the last recorded
admission (his eighth over a 4-year period), this patient was
noted to have massive ascites, marked hepatomegaly, hypoten-
sion (blood pressure: 82/60 mm Hg with an orthostatic drop to
72/58 mm Hg), hyponatremia, and a serum creatinine of 5.8
mg/dl. On previous admissions, the renal insufficiency had
improved with gentle volume expansion and other suitable
supportive therapy. On this last admission, supportive therapy








State University of New York at Stony Brook
and
Tufts University School of Medicine
738 Nephrology Forum: Hepatorenal syndrome
creatinine to 1.9 mg/dl from 5.8 mgldl. Fearing the conse-
quences of the intensive diuresis used to manage the massive
ascites, his physicians elected to treat him with a LeVeen
peritoneovenous shunt. He was able to go home 17 days after
shunt placement with normal serum electrolytes and a serum
creatinine of 1.1 mg/dl; at that time, the patient was edema free
without diuretics while eating a 1.0 g sodium chloride diet (17
mEq Nat/day).
In a 1984 Nephrology Forum, Dr. Gerald DiBona discussed a
patient who had alcoholic cirrhosis and was admitted to the
hospital because of increasing abdominal girth, increasing
edema of the lower extremities, and progressive jaundice [2].
On admission, the patient's blood pressure was 120/70 mm Hg,
and marked ascites and pitting edema of both legs to the level of
the knees were present. The patient was hyponatremic, but the
serum creatinine was 0.8 mg/dl. Appropriate supportive therapy
was started including a low-sodium diet and diuretic therapy.
Insidious oliguria occurred, and the serum creatinine rose to 7.0
mg/dl; severe metabolic acidosis supervened. Gentle volume
expansion did not improve the situation; the patient then
developed pneumonia and died on the 21st hospital day, pre-
sumably from hepatorenal syndrome.
Which, if any, of these 2 patients and today's case truly had
hepatorenal syndrome? The final course of the patient pre-
sented in today's Nephrology Forum is typical of that of many
cirrhotic patients. The patient is admitted to the hospital for
reasons not related to renal failure, usually with a normal serum
creatinine level. A complication such as encephalopathy, upper
gastrointestinal bleeding, or progressive hepatic dysfunction
develops and renal failure then ensues. The patient I presented
had numerous reasons for progressive renal failure. He had
severe vascular disease, was diabetic, had had extensive sur-
gery, developed severe gangrene with sepsis, was treated with
numerous antibiotics (some of which are quite nephrotoxic),
and became progressively hypotensive. There were certainly
good reasons to diagnose acute tubular necrosis (nephrotoxic or
ischemic), severe prerenal failure, or even acute interstitial
nephritis. Hepatorenal syndrome in this clinical setting could
only be a diagnosis of exclusion. Given the terminal events of
extensive vomiting, gastrointestinal bleeding, rapid ascites for-
mation, and progressive hypotension, I believe that hepatorenal
syndrome is in fact an unlikely diagnosis in this patient; the
clinical evidence is sufficient to support a diagnosis of acute
tubular necrosis.
Although the patient presented by Dr. Levinsky left the
hospital without renal failure, he clearly had several episodes in
which progressive azotemia was associated with intravascular
volume depletion secondary to the massive formation of as-
cites. Whenever circulating plasma volume was restored, the
glomerular filtration rate was restored. In the final recorded
admission, volume expansion only partially restored GFR, and
not until a LeVeen shunt was placed did the serum creatinine
fall to the normal range. The multiple episodes of renal failure
clearly were due to hypovolemia (defined as a decrease in the
intravascular, or plasma, compartment). Had the patient not
responded to the LeVeen shunt, however, or if diuresis had
been attempted with potent diuretics, and renal failure had
ensued, most physicians would have diagnosed the classical
prerenal failure resulting from intravascular hypovolemia as
hepatorenal syndrome.
Table 1. Common features of hepatorenal syndrome
Usually appears in hospitalized patients
No apparent clinical causea
Ascites invariably present, jaundice need not be
Some degree of hepatic encephalopathy can be present
Resting blood pressure is usually lower than that previously recorded
for patient
Marked oliguria; urinary sodium concentration actually can be zero
Hyponatremia invariably is present
Urinary biochemical indices usually are those of prerenal failure
rather than ATN
Urinary sediment is scanty
Spontaneous recovery is rare
a Spontaneous GI bleeding; overzealous diuresis or paracentesis,
hypotension, etc., and other similar episodes are properly considered as
adequate cause for prerenal failure.
The patient presented by Dr. DiBona is more stereotypic of
those with the diagnosis of hepatorenal syndrome. Neverthe-
less, the patient presented with progressive ascites and edema
of the legs and with an arterial blood pressure that was probably
on the low side for a 61-year-old man (120/70 mm Hg with an
orthostatic drop). Hyponatremia was present, although the
serum creatinine concentration was normal at presentation. I
shall comment on this point later, but one should not assume
that a normal serum creatinine in the cirrhotic patient reflects a
normal glomerular filtration rate. Acute renal failure developed
only after diuretics and sodium restriction were added to the
therapeutic regime. If further volume contraction were induced
by diuretics, then this patient's subsequent prerenal failure was
more a consequence of severe intravascular hypovolemia than
of some singular cause of renal vasoconstriction, and, accord-
ingly, a diagnosis of hepatorenal syndrome is not justified.
Definition and diagnosis
As I already mentioned, hepatorenal syndrome is an unlikely
diagnosis in today's patient. Moreover, the other two Nephrol-
ogy Forum patients seem more likely to have had hypovolemia
than true hepatorenal syndrome; indeed Dr. Levinsky's patient
is reminiscent of several reports in which acute renal failure in
patients with advanced cirrhosis of the liver was due to hypo-
volemia, and its correction depended on the presence of a
LeVeen shunt to replenish and maintain adequacy of the
circulating plasma volume [3, 4]. Why should we have a
problem diagnosing hepatorenal syndrome?
Hepatorenal syndrome is best defined as acute, progressive,
oliguric renal failure occurring in patients with advanced liver
cirrhosis, the renal failure occurring in the absence of any
apparent clinical cause. Unfortunately, the biochemical distur-
bances in the plasma and urine are the same as those in patients
with "prerenal" or "functional" renal failure. The biochemical
disturbances thus suggest underperfusion of the nephron due to
hypovolemia, reduced cardiac output, or intense renal vasocon-
striction. The usual setting is advanced alcoholic cirrhosis with
ascites, but hepatorenal syndrome also can be present with
other causes of cirrhosis or in severe acute hepatitis; it rarely
occurs in other settings [5, 61. Table 1 summarizes some of the
functional and biochemical disturbances ususally observed in
patients thought to have hepatorenal syndrome.
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What factors lead to difficulties in diagnosing hepatorenal
syndrome? The fact that hepatorenal syndrome occurs most
frequently in patients with advanced hepatic cirrhosis and its
legion of attendant complications, many of which can cause
acute renal failure, is largely responsible for difficulties in
diagnosis (and semantics). As the cirrhotic process advances,
the hepatic venous outflow becomes partially obstructed and
leads to intrahepatic sinusoidal and eventually portal venous
hypertension [7]. Sequestration of blood within the engorged
mesenteric venous circulation and newly developed portasys-
temic venous collateral vessels tends to deplete the "effective
arterial blood volume" unless urinary sodium retention appro-
priately expands the circulating plasma volume. Hepatic and
intestinal lymphatic flow increase dramatically, and the recov-
ered fluid re-enters the venous circulation through the thoracic
duct. When lymph formation exceeds the ability of these
channels to drain lymph into the venous system, ascites collects
within the capacious peritoneal space. To put the issue in
perspective, normal lymphatic drainage in the thoracic duct is
800—1000 ml/day; in the cirrhotic patient, this flow rate can rise
to a value as high as 20 liters/day [71.
In advanced cirrhosis, effective intravascular hypovolemia is
common because of the mesenteric venous sequestration of
blood, the progressive ascites formation, frequent gastrointes-
tinal bleeding, frequent bouts of vomiting and diarrhea, abuse of
diuretics, hemodynamic changes secondary to the opening of
multiple arteriovenous (AV) fistulas, and peripheral arteriolar
vasodilation. Moreover, the large volume of ascites increases
venous pressure in the legs; the increased hydrostatic pressure,
combined with hypoalbuminemia, contributes further to intra-
vascular depletion by sequestering blood and interstitial fluid in
the legs. Thus, the pathophysiologic evolution of the disease
mandates progressive arterial hypovolemia despite the overall
increase in total-body sodium.
Once arterial hypovolemia supervenes, replenishment of the
intravascular volume cannot easily occur, both because of the
disturbed Starling forces regulating transcapillary fluid parti-
tioning and because of the reduced availability of interstitial
fluid. The only available depot of interstitial fluid is the perito-
neal cavity, extensive muscular wasting having depleted other
interstitial fluid stores. Yet efficient reabsorption of ascites into
the circulation is difficult because the portal system is the site of
increased hydrostatic pressure and decreased colloid osmotic
pressure, disturbances that do not favor reabsorption but sup-
port continuing ultrafiltration. Systemic capillaries also "see"
reduced colloid osmotic pressure and thereby increase the
problem of interstitial fluid re-entering the vascular compart-
ment. Consequently, all these patients are at serious risk for
developing arterial hypovolemia because efliux from the arterial
circulation occurs with comparative ease, but vascular replen-
ishment is very difficult. Thus, the creation of incremental
intravascular hypovolemia either by the use of diuretics, sud-
den gastrointestinal bleeding, or an increase in ascites forma-
tion can aggravate hypovolemia sufficiently to cause abrupt
oliguria and renal failure. I believe that the two patients
previously presented fit into this category [1, 21.
Another problem in diagnosing hepatorenal syndrome is that
the serum creatinine level is not an accurate reflection of the
glomerular filtration rate, particularly in cirrhotic patients.
Because of severe muscle wasting, the serum creatinine is
Table 2. Possible causes of hypovolemia in patients with cirrhosis
and renal failure
Vomiting, diarrhea, or both




Edema formation in the legs
Widespread vasodilation, multiple AV fistulae, or both
Reduction in venous return with tense ascites
lower than would otherwise be the case for any given level of
GFR. Thus, a normal serum creatinine level does not necessar-
ily mean a normal glomerular filtration rate. A prospective
study by Papadakis and Arieff of a large number of cirrhotic
patients indicated that the glomerular filtration rate can be
supranormal, normal, or quite depressed even when the serum
creatinine is less than 1.0 mgldl [8]. Moreover, even as GFR
falls, serum creatinine need not rise appreciably. Creatinine
clearance measurements can overestimate true glomerular fil-
tration rate (as measured by inulin clearance) by several hun-
dred percent. Creatinine clearance can be falsely elevated
because of secretion of this substance in the proximal tubule.
Thus, although hepatorenal syndrome represents acute renal
failure that often develops after several days of hospitalization,
it is clear that many cirrhotic patients arrive at the hospital with
markedly depressed renal function that is not immediately
obvious from the serum creatinine level. It is often only a
matter of time before longstanding intravascular hypovolemic
prerenal failure either progresses or turns into overt acute
tubular necrosis.
Other factors also make diagnosing hepatorenal syndrome
difficult. Patients with advanced cirrhosis often have hyperdy-
namic circulations. Despite a low blood pressure and significant
contraction of the effective blood volume, it can be difficult to
appreciate the degree of arterial underfilling clinically. Also, it
is not easy to ascertain that a further critical reduction in
circulating plasma volume has occurred from a previously
depleted steady state. Such a reduction, however, can be
sufficient to induce acute renal failure. Finally, the physician
often encounters difficulty in treating hypovolemia with infu-
sions. Because of the altered Starling forces in the portal tree,
vascular replenishment is difficult. The physician might intend
to expand the circulating plasma volume, but in fact might only
accomplish this transiently, as the administered fluid rapidly
moves into the peritoneal cavity. Hemodynamic measurements
of central volume often are required. Table 2 summarizes some
of the reasons for hypovolemia in patients with renal failure.
A sine qua non in diagnosing hepatorenal syndrome is the
demonstration of selective intrarenal vasoconstnction occur-
ring independently of any known cause of renal underperfusion
such as a depressed cardiac output or intense vasoconstriction
secondary to marked intravascular hypovolemia. What factors
could lead to this renal vasoconstriction? If performance of the
left ventricle were altered, producing, for example, a reduction
in cardiac output, renal ischemia certainly would ensue. All
organs would be subject to underperfusion, however, and the
entire arterial circulation, not just the renal vasculature, would
underfill.
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In addition to left-ventricular malfunction, marked hypovo-
lemia could be present. This perturbation would activate vari-
ous neurohumoral systems, for example, the renal sympathetic
nerves, circulating catecholamines, angiotensin, antidiuretic
hormone, and intrarenal vasoconstrictors. Although intense
renal vasoconstriction could result, the vasoconstriction would
depend simply on the underlying hypovolemia. DiBona empha-
sized the role of efferent renal sympathetic neural activity as a
major determinant for the disturbances in renal function ob-
served in hepatorenal syndrome [2]. It is my view, however,
that unless it can be shown that augmented renal sympathetic
neural activity is a primary disturbance, it cannot be designated
as a cause for hepatorenal syndrome. As long as the augmented
neural activity is secondary to, and dependent on, phenomena
such as hypovolemia, decreased peripheral vascular resistance,
or decreased cardiac output, then insofar as these phenomena
are known to cause renal underperfusion, such neural activity is
not a unique cause for renal vasoconstriction. In any event,
lumbar sympathetic block, which should remove such neural
activity, has been of only modest benefit, producing transient
effects [9].
Third, renal vasoconstriction could result from a reduction in
peripheral vascular resistance. Indeed, evidence indicates that
progressive hepatic cirrhosis is accompanied by widespread
arteriolar vasodilation as well as by the opening of multiple AV
shunts [6]. In hepatorenal snydrome, arterial blood pressure
typically is low. This finding indicates that compensatory vaso-
constriction and a sufficient increment in peripheral vascular
resistance has not occurred despite often large increments in
cardiac output. Schrier et al have proposed that hepatorenal
syndrome is the body's final reaction to a progressive reduction
in peripheral vascular resistance [10]. According to this "pe-
ripheral arterial vasodilation" theory, the "holding capacity"
of the arterial volume increases throughout the cirrhotic pro-
cess. This increase consequently would mobilize the sympa-
thetic nervous system, circulating angiotensin, catecholamines,
and other factors in an attempt to reverse the tendency to
hypotension. As intense renal vasoconstriction became more
severe, renal failure would worsen. This hypothesis, although
interesting, is speculative and leaves several issues unad-
dressed. Hepatorenal syndrome does not occur only in cirrhotic
patients who have a bounding circulation; it also occurs in
numerous patients in whom no evidence for arterial vasodila-
tion exists. Moreover, what evidence is there for a hierarchy of
vasoconstriction so that renal vasoconstriction would take
precedence over constriction in other vascular territories?
Certainly, the administration of aipha-adrenergic blockers to
patients with hepatorenal syndrome does not improve renal
perfusion [11]. Moreover, Gaudin et al recently compared
patients with cirrhosis and portal hypertension with patients
with presinusoidal portal hypertension but without cirrhosis
[12]. Plasma norepinephrine levels were elevated only in the
cirrhotic patients despite an equivalent hyperkinetic circulatory
system in each group. Thus, activation of the sympathetic
nervous system in response to a decrease in peripheral vascular
resistance may require, in the presence of liver disease, a
pathophysiologic process associated with significant elevation
of intrahepatic sinusoidal pressure. A rise in this parameter can
activate low-pressure intrahepatic baroreceptors, which are
known to cause augmentation of efferent sympathetic nerve
stimuli to the kidney and elsewhere [7]. Thus progressive
peripheral arterial vasodilation need not necessarily trigger a
compensatory sympathetic response.
Several case reports indicate that either side-to-side portaca-
val anastomosis or placement of a LeVeen shunt will ameliorate
renal failure in cirrhotic patients simultaneously with normal-
ization of plasma renin and angiotensin levels [3, 4, 13].
Removal of the shunt usually was associated with the reappear-
ance of renal failure. These observations are consistent with the
hypothesis that normovolemia was restored and that removal of
the shunt, because of the perturbations to Starling's forces,
leads to re-formation of ascites, emptying of the vascular
volume, and the reappearance of hepatorenal syndrome.
What evidence indicates that hepatorenal syndrome is due to
selective renal vasoconstriction rather than to the conse-
quences of widespread hypovolemia? Epstein and colleagues,
using angiographic and 133Xe washout techniques to study the
renal circulation of patients with advanced hepatic failure due
to cirrhosis and renal failure thought to be hepatorenal syn-
drome, confirmed the profound reduction in mean renal perfu-
sion in these patients [11]. However, since a similar reduction in
perfusion exists in patients with chronic renal failure, in whom
daily urine output is normal (or even slightly increased), this
reduction cannot be the only cause for the profound oliguria.
Cortical perfusion was reduced, and angiography showed in-
tense vasoconstriction, even of the small-order cortical vessels.
At autopsy, the vascular tree was completely normal (as
assessed by a repeat angiogram) thus proving that the vasocon-
striction had been functional in origin, not anatomic.
Even more telling is that Epstein and colleagues found no
correlation between renal blood flow and level of cardiac output
[14]. Among 20 patients with advanced alcoholic cirrhosis, 10
had elevated cardiac output, 7 had normal output, and 3 had
depressed cardiac output (< 4.0 liters/mm). Renal perfusion
was comparably reduced no matter whether cardiac output was
low, normal, or elevated. This situation is unlike others asso-
ciated with prerenal failure, such as congestive heart failure, in
which cardiac output directly correlates with cortical blood
flow. This observation, as well as the unique vasomotor insta-
bility seen in the 133Xe washout curves in hepatorenal syn-
drome, suggest that local vasoconstrictor influences—possibly
thromboxanes and endothelin—might be critically important in
determining local intrarenal cortical vascular resistance.
Other investigators also have observed a lack of correlation
between cardiac output and renal perfusion. Kew et al [15] and
Hollenberg and coworkers [16] demonstrated that a reduction in
renal cortical perfusion can precede oliguric renal failure in
patients with decompensated cirrhosis. The finding that renal
perfusion in cirrhotic patients is reduced to a far greater degree
than in patients with acute oliguric renal failure who are not
cirrhotic [16] again testifies to the special nature of hepatorenal
syndrome. Ring-Larsen and colleagues measured renal blood
flow in 6 cirrhotic patients who required an end-to-side porta-
caval anastomosis [17]. Portal decompression augmented car-
diac output, but renal perfusion either remained constant or
declined. In studies in the early 1960s, Baldus et al [18] and
Lancestremere et al [19] also noted a lack of correlation
between cardiac output and renal perfusion.
Tristani and Cohn elegantly demonstrated the relationship
between arterial hypovolemia, renal failure, and true primary
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Increments in abdominal venous pressure
Increased circulating catecholamines and/or renal sympathetic
nervous activity
Increased circulating angiotensin
Derangements in intrarenal prostaglandins
Derangements in intrarenal kallikrein-kinin synthesis
Other humoral factors, e.g., endothelin
renal vasoconstriction [201. These investigators studied 21
patients with decompensated cirrhosis and renal insufficiency
before and after the infusion of 500 ml of iso-oncotic dextran.
The patients fell into two groups: (1) Thirteen patients initially
had a depressed cardiac output. These 13 responded to the
volume expansion with dramatic improvement in systemic
hemodynamics and renal blood flow; they thus were distinctly
hypovolemic. (2) Eight patients had normal or elevated blood
volumes and responded to the dextran infusion with only
minimal changes in either cardiac output or renal perfusion. The
authors concluded that in the patients whose circulations im-
proved in response to the dextran infusion, intravascular hypo-
volemia was the probable cause for the oliguric renal failure.
These authors also observed that most patients manifested a
correlation between systemic vascular resistance and intrarenal
resistance, and suggested that the intrarenal vasoconstriction
mirrored a more generalized vasoconstriction secondary to
hypovolemia. Thus, 8 patients (the second group) appeared to
have true hepatorenal syndrome, whereas 13 patients (the first
group) appeared to have hypovolemic prerenal failure.
If hepatorenal syndrome truly originates from isolated intra-
renal vasoconstriction, what is its cause? Several possibilities
have been suggested as the source of the intense renal vaso-
constriction observed in hepatorenal syndrome (Table 3).
Some authors have noted the apparent association between
the deterioration of renal function (apparently unrelated to
volume deficits or altered systemic hemodynamics) and the
appearance or worsening of hepatic encephalopathy [21, 22].
Shear et al suggested that a metabolic abnormality associated
with hepatic coma or precoma induces acute renal failure or
exaggerates a pre-existing abnormality [22]. Indeed, there is a
physiologic precedent for this relationship. Patients who de-
velop subarachnoid hemorrhage or other types of brain insult,
particularly in the frontal area, occasionally develop neuro-
genie" acute renal failure [23], a syndrome associated with
intense cortical vasoconstriction, marked oliguria, and progres-
sive azotemia. The urinary sodium concentration declines to
very low levels. This syndrome of extreme prerenal failure
closely mimics hepatorenal syndrome pathophysiologically,
except in the clinical setting and cause. In dogs, a variety of
central nervous system stimuli (electrical, osmotic, hormonal)
produced severely perturbed renal function [24]. Sitprija and
Tangchai reviewed the literature describing the association
between altered brain function and renal vasoconstriction [23].
The continuous reabsorption of endotoxin from the gastro-
intestinal tract into the circulation of patients with advanced
cirrhosis leads to vasoconstriction of the renal microcirculation
[25]. Although in normal subjects only the terminal colon and
rectum are colonized with bacteria, in cirrhotic patients the
entire gastrointestinal tract, to the level of the duodenum,
becomes densely colonized, presumably because of the pa-
tient's immunosuppressed status. Not only is the source of
endotoxin markedly increased, but disturbances commonly
observed in cirrhosis can promote reabsorption of endotoxin
into the bloodstream. Thus, hypercholesterolemia and jaundice
can promote and facilitate the reabsorption of endotoxin from
the gastrointestinal tract. Because the reticuloendothelial cells
of the liver likely are compromised in advanced cirrhosis,
absorbed endotoxin would not be completely destroyed by the
hepatic Kupifer cells and would appear in the arterial circula-
tion. Although endotoxin is undoubtedly a renal vasoconstric-
tor in humans and other species [26, 271, controversy exists as
to its exact role in producing a functional, prerenal type of acute
renal failure. Most often, where endotoxin is associated with
acute renal failure, it largely appears to be acute tubular
necrosis [28].
Wilkinson and Williams summarized the evidence that endo-
toxins have a causative role in hepatorenal syndrome [26, 271.
These authors cite the observation that endotoxin has been
found in the blood and ascitic fluid of cirrhotic patients who
have hepatorenal syndrome. A 1980 report, however, suggested
that assays are easily contaminated by ambient endotoxin, and
that much of the data in the literature might be incorrect [291.
Because endotoxemia frequently occurs in association with
acute tubular necrosis, and because prerenal failure, rather than
acute tubular necrosis, commonly occurs as an expression of
hepatorenal syndrome, how does one reconcile this association
as cause and effect? Wilkinson and Williams advanced the
thesis that circulating endotoxin in cirrhotic patients causes
reversible vasoconstriction, but that it does not (in most cases)
produce fibrin deposition within the glomeruli and peritubular
regions. If only mild vasoconstriction occurs, acute tubular
necrosis develops. If more marked vasoconstriction and fibrin
deposition occur, then diffuse, severe cortical necrosis ensues
[26]. These investigators also have argued that cirrhotic patients
are uniquely protected against intrarenal fibrin deposition be-
cause of an increased number of heparin-producing mast cells
within the glomerulus and because of increased plasma fibrino-
lytic activity [301. They also cite evidence [31] that patients with
cirrhosis might have high circulating titers of antibodies di-
rected against endotoxin, which would protect against cortical
necrosis secondary to excess fibrin deposition. Thus, moderate
reversible vasoconstriction would lead to hepatorenal syn-
drome, whereas more severe vasoconstriction would lead to
acute tubular necrosis.
These views regarding the role of endotoxins are not gener-
ally accepted, however. Certainly, many patients with prerenal
failure who receive a LeVeen shunt will show improvement in
renal function [13, 32]. Patients reported as having hepatorenal
syndrome also will recover renal function following creation of
a portacaval anastomosis, a procedure unlikely to reduce
gastrointestinal reabsorption of endotoxin.
Other objections that could be raised to the causal impor-
tance of endotoxin include the following: (1) Hepatorenal
syndrome tends to occur only after cirrhotic patients enter the
hospital for one of several complications of severe liver disease.
It seems strange that, if endotoxemia is a major cause, cirrhotic
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patients rarely develop hepatorenal syndrome at home. (2)
Hepatorenal syndrome is often initiated after apparently minor
events, such as paracentesis or diuresis, which are not known
to induce endotoxemia.
False neurotransmitters also have been suggested as causing
renal vasoconstriction in hepatorenal syndrome. Norepineph-
rifle is the usual neurotransmitter in the peripheral autonomic
nervous system. In the presence of severe liver disease, other
hydroxylated phenylethyl amines can replace norepinephrine in
the terminal nerve endings and act as "false" or relatively
inactive neurotransmitters [33]. These substances can be taken
up, stored, and released by nerve terminals in response to usual
physiologic stimuli. If, instead of norepinephrine, false neuro-
transmitters were released, a variety of disturbances could
occur, such as an increment in cardiac output, low peripheral
vascular resistance, and the opening of AV shunts, with diver-
sion of blood away from the renal circulation. These perturba-
tions would explain the hyperdynamic circulation observed so
frequently in patients with hepatorenal syndrome at the same
time they have marked renal vasoconstriction.
The precursors of these false neurotransmitters, such as
tyrosine, are produced in the gastrointestinal tract from protein
by the action of bacterial decarboxylases. Normally, these
aromatic amines are catabolized by monoamine oxidase within
the liver. When liver function is impaired, these precursors
flood the circulation, are locally /3-hydroxylated by nonspecific
enzymes within nervous tissue, and replace the usual neuro-
transmitters. This attractive hypothesis, formulated largely
through the work of Fischer and Baldessarini many years ago
[33], remains unproved and unsubstantiated, but it is worthy of
further investigation.
The literature includes the observation that some cirrhotic
patients with renal failure demonstrate a diminished response to
infusions of tyramine, a sympathomimetic agent that releases
stored norepinephrine from autonomic nerve endings [34].
Other pertinent observations include the findings that cardiac
norepinephrine is reduced in patients and animals with ascites
[35] and that renal vessels are depleted of norepinephrine in
experimental murine ascites [36].
We administered intravenous octopamine (a major "false"
neurotransmitter) to normal and cirrhotic dogs [37]. In normal
controls, octopamine proved to be a hypertensive agent, but it
reduced glomerular filtration rate and lowered effective renal
plasma flow, presumably because of intense intrarenal vasocon-
striction. This amine also had a direct renal tubular effect,
presumably in the more distal parts of the nephron; it increased
salt and water reabsorption. In the dogs with experimental liver
disease, however, octopamine had no pharmacologic effect at
doses that were clearly active in normal controls. These exper-
imental data do not support the notion that octopamine alters
the profile of systemic vascular resistance or reduces urinary
sodium excretion in cirrhotic patients.
More than 25 years ago, Mullane and Gliedman suggested
that pressure on the renal venous system, because of the
presence of ascites, interferes with the renal circulation and
causes renal ischemia [38]. Indeed, these authors suggested that
such increments in renal venous pressure can occur in the
absence of ascites. Direct measurements of renal venous pres-
sure in cirrhotic patients do not support this hypothesis, how-
ever [18]. In any event, many patients with tense ascites, in
whom the pressure exerted on the renal veins exceeds that
attributable to the column of fluid because of muscular elastic-
ity, have stable renal function.
Although Gordon observed transient improvement in renal
function in patients with hepatorenal syndrome following re-
moval of ascites by paracentesis [39], controversy exists con-
cerning this point. Certainly, relieving the pressure on the renal
veins in ascitic patients by placing them in the prone position on
a Stryker frame only transiently improves their renal function
[40]. Increased renal venous pressure as a cause of intense renal
vasoconstriction thus is not a credible hypothesis for explaining
the selective renal ischemia of hepatorenal syndrome.
Increased renal sympathetic nerve activity always must be
considered as a possible cause when one is dealing with
augmented intrarenal vascular resistance. Such an increase in
nerve activity could explain at least some of the abnormalities
observed in hepatorenal syndrome, such as a reduction in renal
blood flow, oliguria, renal hemodynamic instability, and at least
the transient improvement witnessed after the infusion of
various renal vasodilators [411.
Although it seems reasonable to postulate that the intravas-
cular fluid losses so commonly associated with cirrhosis of the
liver would induce generalized vasoconstriction, including the
renal vascular bed, clinical observation and experimental data
do not bear this out. As I pointed out earlier, many patients with
hepatorenal syndrome have bounding circulations and evidence
of peripheral vasodilation. Even if one argues that, for unique
reasons, the vasoconstriction is restricted to the renal circula-
tion, experimental data do not unequivocally support this idea.
Epstein et al infused adrenergic blockers in doses sufficient to
completely blockade the a-adrenergic system in cirrhotic pa-
tients with oliguric renal failure [ill. Yet renal perfusion did not
improve. Although some investigators have been able to in-
crease renal blood flow with renal vasodilators or adrenergic
blockers in cirrhotic patients with renal failure, it is often
necessary to infuse plasma or other fluids to combat the
associated hypotension, and it is not always clear which factors
contribute most to the improved renal blood flow [42]. More-
over, dogs with experimental cirrhosis do not have increased
renal blood flow after a-adrenergic blockade [43]. Although the
matter is not completely settled, there is doubt as to what role
adrenergic-induced vasoconstriction plays in the genesis of
hepatorenal syndrome.
What does seem clear, however, is that as the cirrhotic
process progresses and as patients become ever more hypo-
tensive and intravascularly volume depleted (because of the
formation of large volumes of ascites and edema), the cate-
cholamines, as well as other vasoconstrictors (angiotensin,
antidiuretic hormone) assume a larger role for the maintenance
of arterial blood pressure. As a side effect of this physiologic
trade-off, the elevated plasma levels of circulating vasoconstric-
tors are liable to be associated with a decrement in renal
perfusion. Thus Ring-Larsen et al reported that sympathetic
nerve tone is markedly augmented in cirrhotic patients with
ascites [441. Indeed, such patients, particularly when renal
function begins to deteriorate, show markedly increased nor-
epinephrine spillover into the renal vein. These investigators
have documented a negative correlation between the level of
renal perfusion and renal venous norepinephrine in decompen-
sated cirrhotics. They have postulated that the shift from
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normal renal function to renal decompensation takes place in a
pathophysiologic setting in which plasma levels of catechola-
mines, angiotensin II, and perhaps other vasoconstrictors have
a major, if not a maximal, effect on the renal microvasculature.
If, however, the elevated level of plasma norepinephrine is a
direct consequence of arterial hypovolemia, then the renal
ischemia also can be considered a consequence of the hypovo-
lemia, with norepinephrine acting as a secondary rather than a
primary cause for hepatorenal syndrome. Thus, volume con-
traction simply increases intrarenal microvascular resistance.
Floras and colleagues recently documented that sympathetic
outflow reflects the stage of the cirrhotic process [45]. These
workers obtained direct microneurographic recordings of mus-
cle sympathetic nerve activity from the peroneal nerve of
controls and cirrhotics with and without ascites. In controls,
these were recorded as 17 8 bursts/mm at rest and 65 13
bursts/mm in resting cirrhotics with ascites. Patients without
ascites had intermediate values (34 11 bursts/mm). In one
patient who underwent a liver transplant, burst activity de-
creased from 78 to 6 bursts/mm. These data confirm the
hypothesis that cirrhotics have augmented central sympathetic
outflow. Whether this activity precedes urinary sodium reten-
tion and whether it is responsible for renal vasoconstriction in
the absence of central volume contraction remains to be
proven. A detailed review of the role of renal efferent sympa-
thetic nerve activity in the pathogenesis of hepatorenal syn-
drome can be found elsewhere [21.
Although several lines of evidence suggest that increased
circulating levels of angiotensin II, a potent vasoconstrictor,
play an important role in maintaining arterial blood pressure in
patients with advanced cirrhosis of the liver, it is not clear what
role this peptide plays in the genesis of hepatorenal syndrome.
The evidence that angiotensin assumes a major regulatory
function in the control of hemodynamics in advanced liver
disease, and perhaps in the genesis of hepatorenal syndrome, is
as follows: (1) Patients with advanced cirrhosis of the liver, with
or without hepatorenal syndrome, frequently have marked
elevations of plasma renin and aldosterone [46]. Moreover,
infusions of saralasin or captopril depress arterial blood pres-
sure in patients with decompensated cirrhosis. This finding
indicates the importance of the renin-angiotensin axis for main-
taining normal hemodynamics [13, 471. (2) Whereas, in part, the
increased renin levels might be due to incomplete inactivation
by a diseased liver, there also appears to be an increase in the
actual secretion rate by the juxtaglomerular apparatus [25]. (3)
Barnardo et al adduced evidence that the hyperreninemia
observed in cirrhosis is due to renal ischemia and that improv-
ing renal blood flow lowers plasma renin levels [46]. (4)
Berkowitz and coworkers suggested that the depressed levels of
renin substrate matter more than the increased renin-angioten.-
sin levels [481. Following the infusion of renin-substrate-en-
riched fresh frozen plasma, this group noted increased glomer-
ular filtration rate and urine output in association with a fall in
plasma renin levels. Urine flow and renal function deteriorated
over several days as plasma renin substrate levels fell. More
recently, Cade et al also produced evidence that renin substrate
and hence angiotensin is important for the preservation of renal
perfusion in cirrhotics [49]. When fresh frozen plasma, which
contains renin substrate, was administered to 11 patients with
hepatorenal syndrome, blood pressure and renal perfusion
markedly improved as compared with the response to equiva-
lent methods of replenishing plasma volume without adminis-
tering renin substrate. These authors hypothesized that the
generation of angiotensin II supported the maintenance of blood
pressure. (5) Recent theories for the pathogenesis of acute renal
failure have assigned a special role for high levels of intrarenal
angiotensin as a cause of depressed glomerular filtration rate
and oliguria [50]. Thus, one could argue that angiotensin plays
a major role in producing renal vasoconstriction.
On the other hand, it is entirely possible that the increased
renin secretion observed in hepatorenal syndrome is the result
and not the cause of renal vasoconstriction, and that elevated
plasma angiotensin levels have nothing to with the observed
renal vasoconstriction. Angiotensin has been reported to be
natriuretic when administered to patients with hepatic cirrhosis,
particularly if urinary prostaglandin excretion is elevated [51].
Moreover, the diseased liver is believed to have an increased
ability to destroy angiotensin, because intestine-produced an-
giotensinase inhibitors are believed to bypass the liver during
the course of significant portacaval shunting, which occurs in
virtually every patient with advanced cirrhosis [42, 52]. In fact,
patients with advanced cirrhosis of the liver may be refractory
rather than sensitive to angiotensin [14].
The angiographic studies by Epstein et al indicate that in the
profound vasoconstriction of hepatorenal syndrome, interlobar
and arcuate arteries are profoundly affected [11]. Angiotensin
does not act on these orders of blood vessels [111; thus it is
unlikely that angiotensin could be the sole mediator for the
renal vasoconstriction. Several studies have underlined the
importance of the effective arterial blood volume as a determi-
nant for changes in plasma renin and angiotensin levels [13, 53,
54]. The observation that these levels are acutely suppressed in
cirrhotic patients following intravenous albumin and saline
infusion [541 suggests that they are rising in response to
intravascular hypovolemia. Similarly, Schroeder et al demon-
strated that normalization of plasma volume in patients with
hepatorenal syndrome following placement of a LeVeen shunt
or a portacaval anastomosis decreases the plasma renin, raises
the renin substrate, and obviates the pharmacologic effects of
saralasin, presumably reflecting the diminished physiologic
importance of angiotensin [13]. Moreover, Arroyo and col-
leagues infused saralasin into 3 patients with hepatorenal syn-
drome [53]. In all 3 patients, neither renal plasma flow nor GFR
rose. Thus, removing the pharmacologic effect of angiotensin
does not improve renal perfusion in this syndrome.
Recently Villamediana and coworkers compared the glomer-
ular contractile response to angiotensin in unanesthetized con-
trol and cirrhotic rats and showed that the receptor density for
angiotensin in the glomeruli of the cirrhotic rats was much
higher than in corresponding controls, although affinity was not
different [55]. In the cirrhotic animals, none of which had
ascites, angiotensin did not induce a hemodynamic response
different from that in controls. At least in this relatively "early"
stage of the cirrhotic process, angiotensin had no preferential
effect on the hemodynamics of the experimental animals.
Whether decompensated animals or patients with renal failure
are more sensitive to the vasoconstrictor actions of angiotensin
is not clear.
Wong et al studied the kallikrein-kinin system in 15 patients
with cirrhosis of the liver [56]. Seven had normal renal function,
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and 8 had hepatorenal syndrome. While ingesting a low-sodium
diet (10 mEq/day), patients with hepatorenal syndrome had
undetectable pre-kallikrein or bradykinin levels as compared
with nonazotemic controls. These latter patients, in turn, had
lower levels than normal subjects on a similar diet. The authors
suggested that a relative deficiency of a potent intrarenal
vasodilator in the presence of marked elevations of the renin-
angiotensin system contributed to the vasoconstriction ob-
served in patients with renal failure.
More recently, Perez-Ayuso et al also reported on the kal-
likrein-kinin system in cirrhotic patients [57]. These workers
measured urinary kallikrein activity in 11 control subjects and
31 cirrhotic patients with ascites and preserved renal plasma
flow (PAH clearance) and GFR (inulin clearance). They com-
pared these data with data from 18 cirrhotic patients with
reduced GFR and PAH clearance. Although cirrhotic patients
without renal failure exhibited higher plasma renin, norepineph-
rine, and urinary kallikrein and prostaglandin E2 excretion than
did controls, those cirrhotic patients with renal failure had
lower urinary values for the excretion of both kallikrein and
PGE2 than did the controls and the cirrhotic group without renal
failure, and higher plasma levels for both renin and norepineph-
rine. The level of GFR correlated both with urinary kallikrein
and PGE2 excretion.
Recent experiments have demonstrated that under normal
conditions, intrarenal vascular resistance, and hence renal
blood flow, is maintained in a reasonably narrow physiologic
range because of a balance between constrictor and dilator
influences [58]. Intrarenal vasodilatory prostaglandins play a
major role in modulating the vasoconstrictor effects of angio-
tensin and catecholamines. In clinical conditions in which the
integrity of the circulation becomes largely vasoconstrictor-
dependent, such as cirrhosis of the liver with ascites, the
tendency for augmented intrarenal vasoconstriction increases,
causing a larger dependency on increased renal dilatory pros-
taglandin production to offset these constrictor influences [59].
Under these conditions, the administration of prostaglandin
synthesis inhibitors, such as indomethacin, to cirrhotic patients
with ascites reversibly and dramatically lowers glomerular
filtration rate and renal perfusion, both of which return to
normal on cessation of the drug [60]. This experiment illustrates
the importance of the intrarenal vasodilatory prostaglandins in
successfully modulating the constrictor influences of angioten-
sin and other vasoconstrjctors on the renal microvasculature.
This effect of indomethacin and other inhibitors of pros-
taglandin synthesis also has been demonstrated in dogs with
experimental biliary cirrhosis [61], dogs volume-contracted by
hemorrhage or sodium depletion [62], and dogs with an acute
reduction in cardiac output caused by acute mechanical con-
striction of the thoracic inferior vena cava [63].
The progression of chronic hepatic cirrhosis is associated
with increasing renal production both of vasodilatory and of
constrictor prostaglandins such as thromboxane B2 [64]. Vari-
ous investigators also have adduced evidence that the primary
intrarenal vasoconstriction seen in hepatorenal syndrome is due
to an imbalance of this profile, such that a dilatory pros-
taglandin such as PGE2 decreases, and the production of
thromboxane A2 (measured as the stable B2 metabolite) in-
creases [58]. 1 refer those interested in learning more to several
reviews concerning renal eicosanoids as determinants of renal
function in hepatorenal syndrome [58, 65—67].
Given the fact, as I indicated earlier, that hepatorenal syn-
drome occurs against a background of arterial hypovolemia, it
is tempting to speculate that prostaglandins are essential for
maintaining renal perfusion during advanced states of liver
disease and that hepatorenal syndrome occurs when the intra-
renal synthesis of vasodilatory prostaglandins declines (from
poor nutrition?), leaving unopposed renal vasoconstriction to
produce oliguric renal failure. Tobin and colleagues supported
that view with a report that angioten sin is natriuretic in cirrhotic
patients excreting increased amounts of urinary prostaglandin,
but that angiotensin depresses renal function when urinary
prostaglandins are reduced [51]. A report by Rimola et al also
substantiates this view [59]. These investigators compared the
effects of inhibiting urinary prostaglandin excretion in 44 cir-
rhotic patients with ascites but without hepatorenal syndrome,
with those in 12 cirrhotic patients with hepatorenal syndrome.
The results were correlated with plasma renin and plasma
norepinephrine levels. They demonstrated that cirrhotic pa-
tients without hepatorenal syndrome had high baseline plasma
renin and catecholamine levels and high urinary prostaglandin
excretion. When hepatorenal syndrome was present, renin and
catecholamine levels also were high, but baseline urinary
prostaglandin excretion was significantly reduced. When a
prostaglandin inhibitor was administered to 17 of 44 patients
without hepatorenal syndrome, 9 developed transient acute
oliguric renal failure. The patients whose GFRs fell had signif-
icantly higher catecholamine levels and significantly lower
prostaglandin excretion levels than did those in whom GFR
remained normal after the prostaglandin inhibitor was given.
Their findings therefore support the view that augmented intra-
renal prostaglandin synthesis occurs in advanced cirrhosis and
might protect renal perfusion. However, not all investigators
agree that urinary prostaglandin excretion is elevated in humans
with cirrhosis [67], although evidence indicates that intrarenal
prostaglandin synthesis is increased in canine biliary cirrhosis
[68, 69].
The infusion of pro staglandins into the renal artery in patients
with hepatorenal syndrome confers no clinical benefit [70]. As
Arieff and Chidsey pointed out, however, in advanced liver
disease, renal vasconstriction is so potent that achieving rever-
sal with potent vasodilators might be difficult if not impossible
[71]. Another disturbing finding is the recent report by Epstein
et al [72], who studied cirrhotic patients subjected to total-body
water immersion (to the level of the neck). These researchers
demonstrated that no parallelism exists between the renin-
angiotensin system and intrarenal prostaglandin synthesis [72].
They demonstrated that when cirrhotic patients are immersed
and central hypervolemia is produced, the plasma renin and
aldosterone levels fall markedly, but urinary prostaglandin
excretion increases. Moreover, if indomethacin is given prior to
immersion, basal prostaglandin excretion decreases, but im-
mersion still produces large increments in urinary prostaglandin
excretion despite a fall in plasma renin levels. Thus, other
factors, different from those commonly invoked in producing
vasoconstricijon (that is, increased renin-angiotensin activity)
must influence intrarenal prostaglandin synthesis. Despite the
foregoing observations, it is clear that increased intrarenal
prostaglandin synthesis plays some role in the maintenance of
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appropriate renal perfusion during chronic liver disease. This is
borne out not only in human cirrhotics but also in canine models
[68]. What role, ii any, prostaglandins play in the pathogenesis
of hepatorenal syndrome remains to be clarified.
Although most of the available evidence suggests that cirrho-
sis probably entails a defect in the profile of intrarenal pros-
tagiandin production, only recently did Zipser and colleagues
provide evidence that patients with hepatorenal syndrome—as
opposed to patients with other types of acute renal failure—
excrete increased urinary levels of thromboxane B2 and other
prostaglandin vasoconstrictors [64]. These investigators studied
14 patients with hepatorenal syndrome and found elevated
production of thromboxanes in all. In 3 patients, renal function
spontaneously improved; as renal function improved, urinary
excretion of the vasoconstrictor thromboxane declined. Despite
this observation, thromboxane synthetase inhibitors, although
significantly reducing the production of thromboxanes, have
not had much effect on renal function. Clearly, more work has
to be done in this area to reconcile these confusing findings.
Dunn pointed out that the decreased intrarenal production of
vasodilatory prostaglandins might be associated with the accu-
mulation of the endoperoxide precursors, which could produce
vasoconstriction by occupying appropriate receptor sites [58].
Perhaps receptor-binding blockers rather than inhibitors of
renal thromboxane synthesis should be developed.
In any event, at the moment, enough evidence suggests that
the balance of intrarenal vasodilatory prostaglandins (as well as
other vasodilatory autacoids) with intrarenal vasconstrictor
prostaglandins is crucial in determining whether renal plasma
flow is preserved in patients with severe liver disease [58, 73].
This hypothesis receives support from the observations of
Govindarajan et al, who evaluated prostaglandin synthesizing
capacity in kidneys from patients with hepatorenal syndrome
[74]. Using immunofluorescent techniques, they found that
such capacity was markedly reduced in these patients due to a
loss of cyclooxygenase activity within the medulla. Activity of
this enzyme was normal in patients with acute tubular necrosis
or acute interstitial nephritis. Factors responsible for failure to
regenerate this enzyme in hepatorenal syndrome are unknown.
Not all investigators agree with this position. Recently,
Moore and coworkers measured urinary excretion rates of
major renal and extrarenal metabolites of thromboxane A2 and
of prostacyclin in patients with decompensated cirrhosis, com-
pensated cirrhosis, renal failure, and hepatorenal syndrome;
these values were compared with those from normal control
subjects [75]. The authors controlled for severe hepatocellular
damage by studying patients with severe liver disease but with
normal renal function as assessed by creatinine clearance rates.
The excretion of all urinary prostanoids was increased in the
presence of liver disease, but the rates were highest when
hepatocellular damage was severe; the best correlation was
with serum bilirubjn. These researchers found no evidence that
an altered profile of prostanoid excretion played a role in the
pathogenesis of hepatorenal syndrome.
Several investigations have attempted to define new candi-
dates that influence renal function in the presence of disturbed
liver function. Thus, Lang et al recently demonstrated in rats
that the infusion of glutamine or serine into the portal venous
system (but not the systemic venous system) markedly de-
creases glomerular filtration rate and urine excretion [76].
Section of the vagal hepatic nerve or the renal nerves abolished
this effect. Since glutamine causes swelling of hepatocytes,
these authors suggested that activation of intrahepatic barore-
ceptors initiated a hepatorenal reflex involving augmented
efferent sympathetic nerve traffic to the kidney. This increased
sympathetic signal presumably caused the decline in GFR.
Safirstein and Levitt suggested that the cell swelling of hepatic
disease might, in patients with advanced cirrhosis, initiate a
similar hepatorenal nervous reflex culminating in a reduction in
renal perfusion and GFR, and hence initiate the hepatorenal
syndrome [77]. We have been unable to confirm these observa-
tions in dogs.
Moore and coworkers reported elevated plasma levels of
endothelin, a potent vasoconstrictor, in patients with hepato-
renal syndrome compared with normal controls, patients with
advanced cirrhosis and ascites, and patients with either acute or
chronic renal failure [78]. The mean plasma level in patients
with hepatorenal syndrome was 36 5 pg/mi (n = 10) and 12.9
1.3 in patients with cirrhosis. Normal patients had levels of
endothelin of 3.1 0.4 pglml(n = 7); patients with other causes
of acute renal failure were reported as having levels of 10.1
1.6 pg/mI (n = 10). The lowest value in a patient with hepato-
renal syndrome was higher than the highest value reported in
any other groups. These investigators measured arterial and
renal venous concentration in 7 subjects with liver disease and
found a gradient of at least 4 pg/mi. These data support the idea
that the kidneys themselves generate this potent intrarenal
vasoconstrictor in hepatic disorders.
Cirrhotic patients do not appear to have a deficit of atrial
natriuretic peptide (ANP). Rather, these paients seem to have a
renal tubular hyporesponsiveness to the peptide. Whether any
degree of renal vasoconstriction can be attributed to a relative
lack of ANP is not clear. Certainly, we have no evidence for
such a conjecture at this time. Gerbes et a! did report, however,
that in rats with chronic biliary cirrhosis and ascites, the density
of atrial natriuretic peptide receptors in the glomeruli is in-
creased, but active biologic receptors were decreased in density
[79]. Thus, rats might have been excessively degrading this
peptide. It is possible that a decrease in GFR in cirrhotic
patients is due to a decrease of acute ANP receptors within the
glomerular capillaries, thereby resulting in a decrease in the
functional activity of ANP.
Therapy
The superimposition of either acute tubular necrosis or
so-called hepatorenal syndrome in patients with advanced
hepatic cirrhosis dramatically complicates management. Pa-
tients might not die of renal failure, but its presence can greatly
complicate the patient's already stormy course. Because the
vascular system is often volume depleted, further losses of
circulating volume—even subtle ones—cause a dramatic dete-
rioration of renal function. Diarrhea, vomiting, gastrointestinal
bleeding, excess sweating, or over-zealous diuresis can be
sufficient to initiate a relentless downhill course. Obviously,
these complications should be avoided, if possible.
Although effective intravascular hypovolemia is often
present, its reversal is not a simple matter. Because of the
marked perturbation to Starling forces over an extremely large
vascular territory, that is, the hepatoportal venous tree, infused
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Table 4. Therapeutic options for reversing the intrarenal




Vasodilator prostaglandin analogues (misoprostol)
Dopamine
Peritoneovenous shunting
For future evaluation: calcium-channel blockers, hydralazine pro-
drug
saline or colloid is invariably forced out of the vascular com-
partment into the peritoneal space as ascites. Several dangers
also attend the exuberant infusion of intravenous fluids. First, if
the plasma volume is expanded too rapidly, varices can rupture
and bleed. Second, if more and more fluid is forced into the
peritoneal space, compression of the abdominal vena cava can
limit venous return, and cardiac output can decline, further
worsening renal function. For this reason, paracentesis is often
helpful in relieving tense ascites [801. Drugs that depress the
intrarenal generation of vasodilatory prostaglandins should be
avoided, especially nonsteroidal anti-inflammatory agents,
which can lower GFR dramatically [51.
Given that renal vasoconstriction appears to be the major
problem in hepatorenal syndrome, much of the therapeutic
strategy has been directed at improving renal blood flow. Table
4 summarizes some of the agents used. Most vasodilators have
not been successful or have been only transiently so. Pros-
taglandin infusions have not been helpful, but there is some
promise that oral misoprostol might be. This drug, a synthetic
analogue of the vasodilator prostaglandin E1, has been used in
patients with hepatorenal syndrome. Fevery et al used miso-
prostal in 4 patients with hepatorenal syndrome at twice the
dosage advocated for anti-ulcer therapy, 1600 pg/day in 4
divided doses [81]. When coupled with albumin infusions
(which alone had little effect), misoprostol increased daily urine
output from an average of 328 ml to 1529 ml within 2 to 4 days
after therapy was begun. Serum creatinine fell in each case from
an average of 4.75 mgldl to 1.93 mg/dl, and serum sodium
concentration rose to normal. Despite this promising result, 3
patients died 10 to 40 days later, and one patient required
hepatic transplantation.
Various vasopressin derivatives, such as ornipressin [82] and
octopressin [83], also have been used with favorable results on
GFR and urine output. Lenz et al suggested that an infusion of
ornipressin (6.4 U/hr over a 4-hour period) in patients with
advanced liver cirrhosis and impaired renal function would not
only improve GFR, urine flow, and sodium excretion, but
would normalize systemic hemodynamics [82]. Following the
ornipressin infusion, plasma levels of noradrenaline and renin
normalized; these findings suggested that a hyperdynamic,
vasodilated circulation had been restored to a proper degree of
vascular resistance. Calcium-channel blockers also show some
promise but have not been adequately tested [6].
Other maneuvers such as water immersion and lumbar sym-
pathetic block are, at best, temporary measures. Hepatic trans-
plantation is an option, but organs are scarce and mortality
rates high. If, as I believe, hepatorenal syndrome is a conse-
quence of intense renal vasoconstriction in the presence of a
generally vasodilated state, then identifying the exact mediators
will permit the development of appropriate blockers and inhib-
itors.
Summary
Hepatorenal syndrome is a functional form of acute oliguric
renal failure occurring most often in patients with advanced
cirrhosis of the liver and ascites. Although patients can present
with a normal serum creatinine, the glomerular filtration rate is
invariably reduced significantly, and renal underperfusion (on
the basis of effective hypovolemia and its neurohumoral conse-
quences) probably has been present for a long time. Further
insults to the circulatory volume, even minor ones, can be
sufficient to induce progressive renal failure in a patient who has
had stable, albeit reduced, renal function. Over-zealous diure-
sis, gastrointestinal bleeding, vomiting, diarrhea, excessive
paracentesis, a fall in arterial blood pressure, the appearance or
worsening of hepatic encephalopathy, and the advent of elec-
trolyte abnormalities (hypokalemia, hyponatremia) are com-
mon precipitating factors. Once it develops, oliguric acute renal
failure is rarely reversed.
Most patients diagnosed as having hepatorenal syndrome
probably have prerenal failure on the basis of intravascular
hypovolemia. Volume replacement, appropriate diuresis, the
use of peritoneovenous shunts, or attempts at improving renal
perfusion and/or systemic hemodynamics with ornipressin or
misoprostol may be of help. Some patients will have "true"
hepatorenal syndrome, that is, acute functional renal failure due
to intense intrarenal vasoconstriction, in the absence of arterial
hypovolemia, a compromised cardiac output, or peripheral
vascular resistance. It is not clear which factors mediate the
vasoconstriction, but excess sympathetic nerve activity, throm-
boxanes, or endothelin are possible candidates. Finally, clini-
cians should remember that acute tubular necrosis occurs
commonly in patients with advanced hepatic cirrhosis; in fact,
among such patients, renal failure is more often the result of
acute tubular necrosis than of hepatorenal syndrome [6].
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): What is the mag-
nitude of the plasma volume in cirrhotic patients? Physicians
have argued for years about whether plasma volume is in-
creased, normal, or decreased, partly because of the difficulty
in accurately measuring plasma volume in hypoalbuminemic
cirrhotic patients, in whom the labeled albumin is lost from the
circulation into the peritoneal fluid. How would you suggest we
measure plasma volume or intravascular volume repeatedly in
the cirrhotic patient?
DR. LEVY: I don't agree with your supposition. Many groups
who have measured plasma volume by a variety of techniques
in cirrhotic patients with ascites have shown that these methods
are reliable whether radiolabeled albumin, a marker dye such as
Evan's blue Tl824, or labeled red cells are used [84]. Perhaps
the major reason that albumin or albumin-bound dyes are not
associated with methodologic error is that the measurement is
usually complete within 30 minutes, before appreciable
amounts of protein leak into the peritoneal space or the lym-
phatic dead space. In fact, Lieberman and Reynolds, who first
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suggested the "overfill" hypothesis for ascites formation, stud-
ied patients with a cannulated thoracic duct and showed no
appreciable leakage of radiolabeled marker [84]. My colleagues
and I investigated the possibility of such leakage intensively in
dogs with experimental cirrhosis of the liver. We found no
appreciable loss of marker into the peritoneal fluid or into the
thoracic duct, at least within the first 30 minutes or so. In
studies measuring plasma volume indirectly by the assessment
of red cell mass and arterial hematocrit, calculated plasma
volumes correlate very closely with actual measurements of
plasma volume [85]. There is little doubt that plasma volume
expands in the earliest stages of cirrhosis of the liver, and most
researchers agree that the immediate pre-ascitic stage brings
with it expansion rather than contraction of the plasma volume.
In the cirrhotic patient with ascites, plasma volume is relatively
decreased, not only because of the accumulation of ascites, but
as well because of edema in the lower extremities, repetitive
gastrointestinal bleeding, and invariably, iatrogenic over-diure-
sis coupled with reduced dietary intake of salt.
DR. HARRINGTON: You indicated that as the cirrhotic process
advances, plasma volume declines in most cirrhotic patients.
Yet for many of these hypovolemic patients, the measured
plasma volume isidentical to that obtained in normal controls.
I understand that the plasma volume falls in advancing cirrho-
sis, but if the plasma volume is equivalent to that in normal
individuals, why are these patients perceived as hypovolemic?
In other words, why does the renal handling of sodium differ in
the two groups?
DR. LEVY: Note that cirrhotic patients have a marked in-
crease in the venous holding capacity of the splanchnic circu-
lation, both because of the portal hypertension that engorges
the mesenteric veins and because of the opening up of an
enormous area of venous collaterals. Also, 75% of the splanch-
nic circulation is on the venous side of the mesenteric vascular
tree. The progression of cirrhosis, by virtue of the fact that both
the venous tree and the lymphatic dead space enlarge, thus
mandates a progressive increase in plasma volume. If plasma
volume didn't expand, the patient would die of hypovolemia.
So these patients initially develop hypervolemia because of the
nature of the disease. In addition, arteriolar vasodilation and
the appearance of arteriovenous fistulas further stimulate the
kidney to retain salt and water. Therefore, when the plasma
volume is 100% of normal in the azoternic cirrhotic patient, that
means that there has been a decrement from previously ele-
vated levels, for example, 140% of normal, and that this
reduced volume, although similar in magnitude to the plasma
volume of a normal individual, is insufficient to maintain
physiologic integrity because of the changes that have occurred
in the holding capacity of the venous and arterial circulations.
DR. HARRINGTON: What about the cirrhotic patient who
receives a liver transplant and 6 months later is "normal?"
Have there been followup plasma volume studies to see what
happens in those individuals?
DR. LEVY: I am not sure about such studies, but to the best
of my knowledge, plasma volume normalizes in such patients.
DR. KEITH DRUMMOND (Nephrologist-in-Chief, Montreal
Children's Hospital, Montreal): It surely doesn't matter what
the total plasma volume is in all of this, but it is what the kidney
senses in the arterial tree that is relevant! Don't you agree?
DR. LEVY: Yes.
D. DRUMMOND: So whether or not the plasma volume is
normal or expanded is, within the context of renal function,
irrelevant.
DR. LEVY: I think that is oversimplifying the problem.
DR. DRUMMOND: If all the expanded plasma volume is within
the splanchnic circulation, the kidney should not respond to this
hypervolemia.
DR. LEVY: Yes, the splanchnic bed has increased volume that
it has diverted from the systemic circulation. That's why these
patients retain salt and water in the pre-ascitic or pre-edema-
tous phase. As the splanchnic venous circulation becomes
engorged, a relative hypovolemia concurrently develops on the
arterial side, and the kidneys retain salt and water to compen-
sate. Eventually a steady state is reached in which the total
volume is elevated, but the fullness of the arterial circulation is
normalized. In fact, we have shown in cirrhotic dogs that as the
kidneys retain sodium, the non-portal plasma volume rises
above normal [85]. Our experimental observations [7] lead me
to believe that there is a component of urinary sodium retention
in pre-ascitic cirrhosis that is unrelated to the defense of
extracellular volume but that is caused by low-pressure intra-
hepatic baroreceptors. Others have suggested that, in addition
to an engorged splanchnic venous system, peripheral arteriolar
dilation also causes urinary sodium retention [10].
The situation in pre-ascitic cirrhosis is similar to that which
occurs when a mineralocorticoid and a high-salt diet are given
to experimental subjects. These people retain urinary sodium
but eventually return to salt balance. The physiologic price paid
for that return to balance is an expanded plasma volume.
DR. HARRLNGTON: How do you measure the fullness of the
arterial circulation? You have used that phrase on several
occasions. We can quantify it indirectly by looking at plasma
levels of renin and aldosterone, but can it be measured directly?
DR. LEVY: No. When I speak of the "fullness" of the arterial
circulation, I am connoting a physiologic concept first enuni-
cated by Peters from Yale [86]. In fact, it is an operational, or
functional, definition. When the kidney is not retaining sodium,
and when the hormones that normally mark fullness of the
arterial blood volume—such as atrial natriuretic peptide, renin,
aldosterone, catecholamines—are normal, then the fullness of
the circulation is thought to be normal.
DR. SARAH PRICHARD (Nephrologist, Royal Victoria Hospi-
tal, Montreal): With regard to the volume status of patients with
cirrhosis of the liver and ascites and those who might have
hepatorenal syndrome, the literature shows that some of these
patients respond to an intravenous infusion of ANP, but others
do not. Do you think that this response or lack of response is
simply due to their volume status at the time, or is there a
stronger argument for saying that more complex modulating
factors are somehow involved?
DR. LEVY: The response or lack thereof to ANP in cirrhotic
patients is a somewhat complex situation. The Toronto group of
investigators, Drs. K. Skorecki, Laurie Blendis, and their
colleagues, have adduced evidence that cirrhotic patients with
ascites who do not respond to an infusion of ANP, or who are
indifferent to water immersion, have plasma levels of renin and
aldosterone that are more highly elevated than those in patients
who do respond [871. They also have provided evidence that
distal sodium delivery is a factor in the lack of response to
ANP. This seems not to be true in the cirrhotic dogs we studied
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in collaboration with Dr. Legault [881. Cirrhotic dogs and
chronic caval dogs with ascites show a heterogeneity of natri-
uretic response to ANP: 50% of animals respond with a normal
natriuresis: 50% display complete insensitivity to the peptide.
Until recently, these dogs appeared to be physiologically equiv-
alent. However, we recently provided evidence of a critical lack
of kinins reaching the distal nephron in the dogs not responding
to ANP [89]. There appears to be a critical amount of intralu-
minal kinins that must be available in salt-retaining dogs for
ANP to induce a natriuresis. In a study published several years
ago, Drs. Bichet and Schrier showed that cirrhotic patients can
be divided into "excretors" and "non-excretors" with regard
to a water load [90]. The normal excretors of water were the
patients who did not have ascites and in whom markers of the
fullness of the circulation were within normal limits. The
patients unable to excrete water had plasma levels of renin,
aldosterone, antidiuretic hormone, and catcholamines; presum-
ably, these patients had some degree of contraction of the
effective arterial blood volume. Dr. Legault, do you wish to add
any comments?
DR. Louis LEGAULT (Nephrolo gist, Hôpital St. Luc, Mon-
treal): I agree that the physiologic response or lack of response
to the natriuretic effects of ANP appear to differ between dogs
with ascites and cirrhotic patients. Cirrhotic patients who
apparently had extreme hypovolemia do not respond to ANP.
When hypovolemia was corrected with infusions of colloid or
mannitol, and we were able to increase distal sodium delivery,
some of these patients, but certainly not all, regained a natri-
uretic responsiveness to ANP. As you pointed out, Dr. Levy,
this situation differs from sodium-retaining chronic caval dogs
with ascites, in which distal delivery appears to be identical in
responders and non-responders, but the non-responders appear
to lack critical amounts of kinins in the lumen of the distal
nephron [89].
Da. TOM HUTCHINSON (Nephrolo gist, Royal Victoria Hos-
pital, and Director, Division of Clinical Epidemiology, Royal
Victoria Hospital): Dr. Levy, you seem to want to get rid of the
term "hepatorenal syndrome." Would it not be wiser to admit
that the hepatorenal syndrome does indeed exist, but that one
of the major etiologic mechanisms for this syndrome is volume
depletion that is diflicult to correct? By analogy, would you
want to get rid of the term "congestive heart failure" because
expansion on the venous side of the circulation, while causing
edema, also causes problems on the arterial side because of
volume contraction?
DR. LEVY: Let me turn that statement around. If you have a
patient with bona fide heart failure in whom there is no question
of the diagnosis, and signs and symptoms are appearing because
of pulmonary edema and inability of the heart to deal with the
venous preload, but at the same time there is oliguria and
progressive azotemia because of contraction of the arterial
volume, would you call that "cardiorenal syndrome" simply
because the failing heart is associated with underperfusion of
the nephrons? I think not. Using the same analysis, in a patient
who has abruptly developed nephrotic syndrome and has
translocated large amounts of plasma into the interstitial space
as edema and is now suffering from a contracted circulation
with progressive azotemia, would you call that "albuminorenal
syndrome?" I think using the term "hepatorenal syndrome" is
substituting jargon for pathophysiology. Clearly we are not
surprised when a patient with congestive heart failure develops
oliguria, azotemia, and prerenal failure, because we recognize
that there is a distinct physiologic cause for underperfusion of
the nephrons. We also must recognize that in progressive
cirrhosis of the liver, there are specific causes for arterial
hypovolemia and that many of these patients will develop
progressive azotemia and prerenal failure. I think substituting
the term "hepatorenal syndrome" deflects physicians' atten-
tion from the nature of the problem. If indeed there is a problem
of contracted circulating plasma volume, many of these patients
can be helped with either infusions of colloids or with a LeVeen
peritoneovenous shunt. If, on the other hand, there is a primary
decrease in peripheral vascular resistance, then a vasoconstric-
tor such as ornipressin might be indicated. What we really
should be doing in these patients is documenting with appropri-
ate studies the cause of the renal underperfusion and reacting
accordingly. In my view, the term "hepatorenal syndrome"
should be used in situations in which the oliguria is produced by
some primary cause for renal vasoconstriction. "Hepatorenal
syndrome" should not be used in patients with either a con-
tracted plasma volume or a marked increase in holding capacity
of the circulation, that is, a major decrease in peripheral
vascular resistance. I believe that the majority of patients who
are diagnosed as having hepatorenal syndrome really have an
underfilled arterial circulation either because of primary hypo-
volemia or a primary reduction in peripheral vascular resis-
tance.
DR. PAUL BARRE (Nephrolo gist, Royal Victoria Hospital):
Do you think the hepatorenal syndrome is largely iatrogenic? It
seems to me that it is rare to see cirrhotic patients come into the
hospital or to an Emergency Room with this syndrome. If it
exists, it almost always seems to occur in the hospital. The 3
patients that you reviewed for us seem to emphasize this point.
DR. LEVY: Your statement has a lot of merit. Numerous
groups have reviewed their data and little doubt exists that what
the medical profession is calling hepatorenal syndrome com-
mences only after a hospital admission. This is not to say that
renal function is not impaired before the patient enters the
hospital, but the progressive renal failure seems to occur only
after a hospital admission. The most reasonable conclusion is
that we are removing patients from their source of salt and
possibly further complicating the situation by administering
diuretics. I often have wondered whether the abrupt removal of
alcohol from some patients is a causative factor. As you know,
alcohol has potent effects on intracellular enzymes, and it may
be that the abrupt removal of alcohol in some way alters hepatic
synthetic or degradative capacity. I don't think that the hypoth-
esis that restoring a patient's alcohol level will terminate
hepatorenal syndrome has ever been tested.
DR. HARRINGTON: Do you mean we should be giving these
patients Guinness stout?
DR. LEVY: The one hypothesis that has never been tested is
that the best way to terminate hepatorenal syndrome is to
replace the patient's previously generous alcohol intake. Al-
though I give this answer somewhat with tongue in cheek, I
hasten to point out that there are patients with cirrhosis of the
liver that is non-alcoholic in origin, such as the patient pre-
sented in the present Forum, in whom abrupt removal of
alcohol would not be considered a causative factor.
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DR. MICHAEL DAVIDMAN (Nephrolo gist, Sir Mortimer B.
Davis-Jewish General Hospital, Montreal): Many cirrhotic
patients, when given volume replacement intravenously, do not
respond with an improvement in renal function. Indeed, some-
times these patients develop more ascites. Although I recognize
that it might be difficult to maintain infused volume within the
vascular tree, should we not consider redefining hepatorenal
syndrome as affecting those patients who do not respond to the
LeVeen peritoneovenous shunt? Also, is it possible that the
placement of a LeVeen shunt accomplishes other things than
just the redistribution of extracellular fluid volume?
DR. LEVY: You raise an interesting point. Purely on prag-
matic grounds one could diagnose the presence of true hepato-
renal syndrome in patients who do not respond appropriately to
the insertion of a LeVeen shunt. However, one must be
absolutely certain that acute tubular necrosis (ATN) is not
present. Frankly, I suspect that many cirrhotic patients with
prolonged prerenal failure already have ATN when they are
seen by a nephrologist. These are patients who have been
hypovolemic for a very long time and in whom GFR has been
reduced for a long time. In fact, when epithelial cells shed into
the urine of patients with hepatorenal syndrome are examined
by electron microscopy, they resemble cells from patients with
bona fide ATN more than they do cells from patients known to
have true prerenal failure [91]. Dr. Levinsky noted many years
ago that the urine sediment of the jaundiced patient resembles
that seen in ATN [921. Your statement has merit, provided one
remembers the caveat that many of these patients might have
true ATN that is difficult to diagnose.
The other point you raise, whether a LeVeen shunt accom-
plishes things other than restoring volume, is a good one. I have
always been impressed by the fact that within 2 to 3 days of
insertion of a LeVeen shunt in a cirrhotic patient with refrac-
tory ascites who was virtually terminal and looked positively
emaciated, good health is suddenly restored. The patient's face
becomes full, and nutrition seems to improve markedly. I often
wonder whether this remarkable return to health can in some
way be attributed to a return to the circulation of large amounts
of protein from the peritoneal space. I am not sure that this
problem has been adequately addressed by investigators.
DR. PETER SOMERVILLE (Acting Nephrolo gist-in-Chief,
Montreal General Hospital): My question relates to the differ-
ence between hepatorenal syndrome and ATN. It seems to me
that patients with hepatorenal syndrome have slowly rising
levels of serum creatinine while the urinary sodium is often very
low for many weeks. Yet in all types of ATN, the urinary
sodium often is high and represents damage to the tubules.
DR. LEvY: I am not sure that I agree with your statement.
Many patients with ATN, particularly those with the nonoligu-
nc form, have a low urinary sodium level. My hypothesis has
been that in these patients the excreted urine comes from very
deep cortical nephrons with long loops of Henle extending
almost to the papillary tip where there is considerable opportu-
nity to lower urinary sodium. It is well known that there is a
graded sensitivity of nephrons to an ischemic insult. The more
superficial nephrons are more susceptible to renal ischemia,
presumably because of very high levels of renin in the juxta-
glomerular apparatus. The renin concentration virtually disap-
pears on approach to the corticomedullary junction, and I think
that these nephrons are escaping ischemic damage and provid-
ing the urine that we see, particularly in patients with nonolig-
uric ATN. Although there is probably a correlation between
ATN and elevated levels of urinary sodium, I don't think it is a
particularly strong one. We see many patients in consultation
who have unequivocal ATN but in whom the urinary sodium
concentration is quite low. My guess is that the many patients
who are thought to have hepatorenal syndrome, in part because
of the biochemical profile of the urine, in reality already have
established ATN.
In regard to the slow rate of rise of serum creatinine in
patients with hepatorenal syndrome, the situation is somewhat
complicated by the fact that this variable per se is usually not
representative of the GFR because of the profound muscle
wasting. I believe the rate of rise is extremely variable and can
be slow or rapid.
DR. PAUL GOODY ER (Nephrologist, Department of Paediat-
rics, Montreal Children's Hospital): We have had an epidemic
over the last year of hepatitis A virus in the Canadian Arctic.
My colleagues there tell me that this has been a particularly
virulent epidemic. Indeed, 9 Inuit children have been trans-
ferred to the Montreal Children's Hospital with fulminant
hepatitis. Of these 9, 8 have had significant acute renal failure.
Do you think that the pathophysiology in this setting is different
than what you describe in patients with advanced cirrhosis and
ascites?
DR. LEVY: I am sure that it is, because there are some
important differences in the two clinical situations. First, the
patients with virulent hepatitis have abrupt and fulminating
cellular necrosis that probably is not present in patients with
advanced cirrhosis. Second, patients with fulminating hepatitis
invariably have severe and marked jaundice. Although cirrhotic
patients can be jaundiced, it tends to be low grade in most
patients. I would remind you that when bilirubin levels become
high, perhaps on the order of 15 mg/dl or higher, particularly in
susceptible patients with either renal ischemia or a significant
degree of hypovolemia, jaundice can represent a marked insult
to the kidney. I believe that patients with previously normal
renal function can develop renal failure on the basis ofjaundice
alone.
DR. HARRINGTON: Let me follow up on the previous ques-
tion. Did any of the children with hepatitis die? Do you have
information on the renal morphology? Did any of the children
receive liver transplants? What happened to renal function
when they recovered from hepatitis A?
DR. RICHARD SCHREIBER (Pediatric Gastroenterologist, De-
partment of Paediatrics, Montreal Children's Hospital): From
this hepatitis epidemic, 9 children were sent to our hospital with
focal hepatitis, heptic encephalopathy, and severe jaundice
within 2 weeks of the onset of their hepatitis A. They all
developed some degree of renal failure. That gave us an
incidence of fulminant failure of about 5% in that population, or
approximately 10 times the rate previously reported in the
literature [93]. Of the 9 children, 2 died and none of the others
required liver transplantation. Of these 9 children, 8 presented
with severe renal failure, and one required dialysis. Only one
child had an autopsy. The morphologic details of the kidney
were more or less intact. There was mild vascular and glomer-
ular congestion. A few granular and pigmented casts were
observed in tubules. The interstitium was completely normal.
The glomeruli were otherwise normal, and some proximal
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tubules showed mild vacuolation, thought to be compatible with
the mannitol infusion that had been administered. There was no
evidence of ATN.
DR. DANIEL BICJ-iET (Nephrolo gist, Hôpital Sacré-Coeur,
Université de Montreal): First, I have a comment concerning
assessment of blood volume, which you discussed earlier.
Measurements of blood volume can be confusing in cirrhotic
patients because the numbers often are related to so-called dry
weight. Yet, when one performs these measurements repeat-
edly, varying amounts of edema often are present. I agree,
however, that blood volume is elevated in the pre-ascitic stage
of the disease. I also agree that measurements using either
radiolabeled albumin or albumin-bound markers are accurate.
Second, I am confused about your argument concerning
patients who have received LeVeen shunts. Although undoubt-
edly plasma volume is replenished with this device, other things
are also happening, such as an increase in cardiac output and a
decrease in intra-abdominal pressure. How can you be sure that
it is simply replenishment of the plasma volume that is the
major factor in improving renal function in these patients? I
agree with you that the basic underlying lesion in hepatorenal
syndrome is a decrease in the fullness of the arterial circulation
as perceived by the kidney. I am not convinced, however, that
other factors are operative. Certainly, in patients who have
functioning LeVeen shunts and who respond to this procedure
with a normalization of renal function, it is difficult to postulate
that they had a circulating hepatotoxin that induced renal
vasoconstriction. I don't think that hepatorenal syndrome is a
special type of disease induced by some mysterious factor yet
to be discovered.
DR. LEVY: I am pleased that you agree with my underlying
hypothesis that most patients who are diagnosed as having
hepatorenal syndrome simply have a severe reduction of the
so-called effective arterial blood volume. I agree that the
placement of a LeVeen shunt also decreases intra-abdominal
pressure and increases cardiac output. Certainly the simulta-
neous raising of the cardiac output, and the normalization of
plasma levels of renin, aldosterone, catecholamines, etc., all
play a role in improving renal function. Nevertheless, the
central event is restoration of plasma volume, which then
secondarily affects all these other compensatory mechanisms. I
really do not think that a decrease in intra-abdominal pressure
plays any role here. Previous studies have shown that where
only intra-abdominal pressure is relieved, at best glomerular
filtration rate and renal perfusion only transiently improve [39].
DR. BICHET: Yes, but you have to simultaneously expand
plasma volume and decrease intra-abdominal pressure. Don't
you think that you are being somewhat glib in interpreting the
results of LeVeen shunt placement in the case discussed by Dr.
Levinsky [lJ? Are you not oversimplifying the matter if you
dismiss all cases of acute prerenal failure (on the basis of
arterial hypovolemia) in cirrhotic patients as being different
from hepatorenal syndrome as it is currently defined?
DR. LEVY: No, I do not think I am being frivolous in saying
that patients such as the one presented by Dr. Levinsky did not
have hepatorenal syndrome since they were prevented from
developing this problem by placement of the LeVeen shunt.
You must remember that this patient and other such patients
presented in the literature had advanced, acute prerenal failure.
The patient whom Dr. Levinsky discussed had been admitted to
the hospital 8 times over a 4-year period with exactly the same
phenomenon. I really believe that the LeVeen shunt was not
only replenishing plasma volume, but was preventing the as-
cites from re-forming. I know of no other rational interpretation
except that this patient had severe hypovolemia from ascites
and possibly other factors and that insertion of the LeVeen
shunt corrected this problem.
Dr. Bichet, I believe we are saying the same thing, but in
different ways. There is no doubt in my mind that the central
problem of the patient with advanced cirrhosis, ascites, and
renal failure is a compromise of the integrity of the arterial
blood volume. This integrity can be compromised on the basis
of primary hypovolemia (for example, due to excessive diure-
sis), the formation of large volumes of ascites, or bleeding from
esophageal varices. The plasma volume can remain nearly
normal, but the degree of arterial fullness can decrease either
because of primary vasodilation or the opening of AV shunts. In
one case you might want to increase volume, but this is very
difficult in the cirrhotic patient because of the marked pertur-
bation of Starling forces over the entire hepatoportal vascular
tree. In the other case, one might wish to give a vasoconstrictor
like ornipressin. In any event, it is clear that improvement of
renal function will occur when one restores the fullness of the
arterial circulation. That is why I believe that we should use the
term "hepatorenal syndrome" only after we are sure that
systemic hemodynamics and circulating plasma volume are
within normal limits. Otherwise, we deflect the physician's
attention from what really needs to be done, and we introduce
a term that can be misleading. Like you, I believe that there is
probably no mysterious renal vasoconstrictor, but that an entire
family of vasoconstrictors is reacting to primary changes in
fullness of the arterial circulation.
DR. MARCELO CANTAROVICH (Assistant Professor of Medi-
cine, Transplantation Service, Royal Victoria Hospital): So-
called hepatorenal syndrome tends to occur in patients who
have advanced liver cirrhosis. Do you know of any study
looking at the outcome in terms of mortality with regard to
either medical management, a portacaval shunt, or the place-
ment of a LeVeen shunt?
DR. LEVY: To the best of my knowledge, the placement of a
LeVeen shunt or the creation of any of the types of the
portacaval anastomoses has not been successful in prolonging
survival in these patients. Over the long term, I don't believe
there are differences in outcome among the choices you men-
tioned.
DR. CANTAROVICH: Do you think such patients should be
considered earlier for liver transplantation?
DR. LEVY: Given the great need for donor livers and the
scarcity of such donors in Canada, I doubt that this would be a
practical solution to the problem in the foreseeable future.
DR. ALEX ARONOFF (Gastroenterolo gist, Department of
Medicine, Royal Victoria Hospital): We often see patients with
hepatorenal syndrome who do not have any evidence of hepatic
encephalopathy; I am not sure what causative role this might
play. I always have had the feeling that the renin-angiotensin
system is extremely important in the pathogenesis of this
syndrome. As you know, we tend to use rather large doses of
spironolactone, which often are successful in initiating a diure-
sis. Have physicians tried ACE inhibitors in an attempt to
improve the situation?
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DR. LEVY: I don't believe that you can invoke the efficacy of
spironolactone in treating cirrhotic patients with refractory
ascites as proof that the renin-angiotensin system is involved in
hepatorenal syndrome. Hyperaldosteronism is common in
these patients, but spironolactone is successful in initiating a
diuresis and natriuresis because it is such a weak, indolent
diuretic. I believe that its very success depends on the fact that
the diuresis is mild and takes a long time to get started. It is this
very indolence that permits adequate replenishment of the
vascular volume from the large depot of ascites that then
permits perpetuation of the diuresis without throwing the pa-
tient into renal failure. The problem with furosemide and other
such potent diuretics is that emptying of the arterial tree occurs
more quickly than it can be replenished, and these patients
often then quickly go into renal failure.
DR. ROLF LOERTSCHER (Physician, Transplant Service,
Royal Victoria Hospital): Do you think we should be using
volume replacement or vasoconstrictors initially in the treat-
ment of hepatorenal syndrome?
DR. LEVY: Probably one should try judicious volume replace-
ment initially, but the problem is that often this approach fails
because the infusate enters the peritoneal space. That is why
the LeVeen shunt has proved efficacious over the short term. It
prevents circulating plasma from being sequestered in the
peritoneal space. Unfortunately, it has other problems. Cer-
tainly one would use a vasoconstrictor if one could show that
marked vasodilation were present. Unfortunately, this is often
difficult unless one can obtain the appropriate hemodynamic
measurements in an Intensive Care Unit. I hope that more
studies will become available with agents such as ornipressin.
DR. HARRINGTON: Are there selective vasoconstrictors that
should be used?
DR. LEVY: The antidiuretic hormone and its analogues pref-
erentially vasoconstrict the splanchnic tree [83]. That is why
agents such as omnipressin and ornipressin have been success-
ful, at least over the short term, in improving the fullness of the
arterial blood volume and increasing peripheral vascular resis-
tance. More work is needed in this area, however.
DR. ANDREW GONDA (Nephrologist, Royal Victoria Hospi-
tal): Are you convinced that there are patients who, in the
absence of intravascular volume depletion or gross peripheral
vasodilation, appear to have selective renal vasoconstriction?
DR. LEVY: Previous studies such as those I mentioned by
Tristani and Cohn describe such patients [20]. I am not saying
that such patients do not exist, but I believe that the vast
majority of patients with advanced cirrhosis, ascites, and renal
failure who have been diagnosed as having hepatorenal syn-
drome have either severe hypovolemia or a markedly vasodi-
lated peripheral vasculature.
DR. LEGAULT: Dr. Levy, I agree that many of these patients
should be studied in an Intensive Care Unit. I believe that if
appropriate therapy is given, that is, either fluid replacement or
vasoconstrictors, most patients will respond as you have sug-
gested. In my experience, however, renal vasoconstriction
cannot be reversed in a small percentage of patients.
DR. DAVIDMAN: In view of Dr. Legault's comments, Dr.
Levy, do you believe that these cirrhotic patients have primary
sodium retention and have predominantly vascular overfill?
DR. LEVY: Experimental data from my laboratory in dogs
with experimental cirrhosis [5], and most of the clinical data in
patients with advanced cirrhosis [10], support the concept of
volume expansion because of pre-ascitic sodium retention.
However, the evolution of this disease over years or even
decades eventually results in a progressive reduction in the
intially expanded plasma volume. Such reduction comes about
in large part because of the encounter between an expanded
plasma volume and progressive perturbations to Starling forces
over an extensive area of the vascular tree, as I have discussed.
The time when the plasma volume begins to decline, because of
the formation of a large volume of ascites, and because of the
reduction in peripheral vascular resistance, is the time when
renal function may deteriorate. At this point, often after many
years, the kidney behaves as if the patient's intravascular
volume is markedly underfilled.
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